CYRX News & Events

Consensus is for FY25 revenue $171.2M.

Reports Q3 revenue $44.2M, consensus $41.22M. Jerrell Shelton, CEO of Cryoport, commented, "Q3 was another outstanding quarter for Cryoport with 15% year-over-year growth in revenue from continuing operations. During the third quarter, we continued to see strong momentum, with double-digit growth. A driver of our total Q3 revenue was from the support of commercial cell and gene therapies, which grew 36% year-over-year to $8.3M. Our Q3 Life Sciences Services revenue increased 16% year-over-year, representing 55% of total revenue from continuing operations. This included a 21% rise in BioStorage/BioServices revenue, reflecting continued strong demand for our integrated platform. We also saw encouraging signs of stability in our Life Sciences Products segment, where revenue grew 15% year-over-year, supported by sustained demand for our market-leading cryogenic systems. Cryoport continues to demonstrate a visible pathway to profitability with improvements in adjusted EBITDA and a solid gross margin of 48% in Q3, while continuing to invest in our priority growth initiatives to drive long-term value."

Cryoport announced the launch of its newest, state-of-the art facility in Louvres, France, through its subsidiary, Cryoport Systems. The facility, which is strategically located near the Paris Charles de Gaulle Airport, marks a strategic expansion of Cryoport Systems' Global Supply Chain Center network, which offers end-to-end temperature-controlled supply chain solutions and capabilities. Purpose-built to streamline operations and address critical challenges in the advanced therapies market, the facility provides end-to-end, temperature-controlled supply chain solutions under one roof. As the third global supply chain center campus in Cryoport's network, it will offer global accessibility for biopharma and other temperature-sensitive commodities.